ACC 2022: Triple Therapy - When to Use and How Long

ACC 2022 Conference Coverage

D. Kumbhani

DAPT Following ACS: Does One Size Fit All?

Canadian Collaborative Research Network

M. Bonaca

Time to Retire Aspirin?

Top Ten Topics in Clinical Cardiology 2021

R. Mehran

Aspirin for the Primary Prevention of Cardiovascular Disease: What C…

Houston Methodist DeBakey Heart and Vascular Center

M. Miedema

ACP 2024 Insights: Acute Coronary Syndromes - Evaluation, Diagnosis …

Insights from 2024 ACP Annual Meeting

D. Berg

Treating Stenosis or Ischemia Does Not Improve Outcomes: Medical The…

Cedars Sinai

W. Boden

How to Manage Anticoagulation in Patients With Inherited Bleeding Di…

Bethany Samuelson Bannow

Perioperative Management of Antithrombotic Therapy

CHEST 2022 Coverage

J. Douketis

Ticagrelor with or without Aspirin in ACS after PCI (TICO)

American College of Cardiology

P. Block, Y. Jang

Perioperative Considerations for Anticoagulation With Mechanical Dev…

James Douketis

Aspirin & Primary Prevention: What Do the Guidelines Say?

Houston Methodist DeBakey Heart and Vascular Center

M. Gulati

ESC 2023 Insights: STOPDAPT-3 - Study to Evaluate Safety of No Dual …

ESC 2023 Insights

M. Natsuaki

MASTER DAPT: Dual Antiplatelet Therapy After PCI in Patients at High…

American College of Cardiology

V. Fuster, D. Itchhaporia, M. Mack, C. Albert, J. Grapsa

Highlights and Critiques of ACC/AHA/SCAI Revascularization Guidelines

ARCH Advanced Revascularization Symposium

D. A. Cox

Bivalirudin vs Heparin: Trial Designs, Ischemic and Bleeding Outcomes

San Diego Cardiovascular Interventions (SDCI) 2019

R. Reeves

Stable CAD: ASA Alone, Prolonged DAPT or Low-Dose Rivaroxaban?

Canadian Collaborative Research Network

M. Sabatine

Stress Testing in the Real World

Northwestern Medicine Bluhm Cardiovascular Institute

M. Eimer

AHA 2022 Debate: Should CABG Be Level IIB for Improving Survival Com…

AHA 2022 Conference Coverage

F. Bakaeen

The Use of Coronary Artery Calcium Score to Determine Benefit of Asp…

The Texas Heart Institute

E. Hernandez

COVID-19 Cardiac Complications

3rd Advanced Lung Disease: Novel Therapies and Controversies Conference

B. Bozkurt